News Sentiment

RXRX sentiment intelligence

Recursion Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 70 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.56 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

86/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-6.3% over one week, +13.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 86/100 classification
One-week reaction -6.3% Price reacting lower
Trend fit Trend inactive 13.0% over four weeks
Fair value -46.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 48
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 19
Market source 11
simplywall.st 7
TradingView 4
Quiver Quantitative 4
Sahm 3
Motley Fool 2
Stocktwits 1

Event Lens

What the news is about

Classified themes
Market update 51
Earnings 14
Balance sheet 3
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 70
Investing.com India Direct company coverage

Recursion Pharmaceuticals director Borgeson sells $158,500 stock By Investing.com

Recursion Pharmaceuticals director Blake Borgeson sold 40,000 shares of Class A Common Stock for a total of $158,500, pursuant to a Rule 10b5-1 trading plan. The sale occurred on July 7, 2026, with shares sold between $3.95 and $4.00. This transaction leaves Borgeson with 6,218,2

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:41
Source
Investing.com India
Stock Titan Direct company coverage

Recursion Pharmaceuticals (RXRX) director sells 40,000 shares in 10b5-1 trade

Recursion Pharmaceuticals (RXRX) director Blake Borgeson sold 40,000 shares of Class A common stock on July 7, 2026, at a weighted average price of $3.9625 per share, totaling approximately $159,000. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in

Tone
Negative 39/100
Event
Market update
Published
10 Jul 2026 09:39
Source
Stock Titan
Stock Titan Direct company coverage

Recursion Pharmaceuticals (RXRX) director granted 5,109 Class A shares

Recursion Pharmaceuticals (RXRX) director Zavain Dar was granted 5,109 Class A shares at no cash cost under the company’s Outside Director Compensation Policy. Following this award, Dar directly holds 240,764 Class A shares. This transaction was reported in a Form 4 filing and ca

Tone
Neutral 50/100
Event
Balance sheet
Published
02 Jul 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Recursion (NASDAQ: RXRX) director Dean Y. Li receives 3,747-share equity grant

Recursion (NASDAQ: RXRX) director Dean Y. Li has received an equity grant of 3,747 Class A shares as compensation under the company’s Outside Director Compensation Policy. This grant increases his direct holdings to 1,473,329 Class A shares. Additionally, Li indirectly holds 421,

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Christopher C. Gibson lists multiple Class A sales (RXRX)

Christopher C. Gibson, an insider at Recursion Pharmaceuticals, Inc. (RXRX), has filed a Form 144 notice for proposed sales of Class A common stock. The filing details several disposition dates and share quantities, including a significant 100,000 share entry dated July 1, 2026,

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 16:55
Source
Stock Titan
Stock Titan Direct company coverage

RXRX (NASDAQ: RXRX) insider sale notice — 100,000 Class A shares

Recursion Pharmaceuticals (NASDAQ: RXRX) has filed a Form 144 disclosing a prospective sale of 100,000 Class A shares resulting from restricted stock vesting on May 15, 2025. The filing also notes previous dispositions by Christopher C. Gibson, including 340,440 shares sold for o

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:39
Source
Stock Titan
TradingView Direct company coverage

Recursion Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:RXRX)

This article provides an overview of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions regarding the stock's ticker, price volatility, earnings rep

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 14:09
Source
TradingView
TradingView Direct company coverage

8RL Forecast — Price Target — Prediction for 2027

This article provides a forecast for Recursion Pharmaceuticals, Inc. Class A (8RL) stock, including a price target of 5.69 EUR based on analyst estimates. It outlines key financial metrics such as recent earnings and revenue, and provides information on employee count and EBITDA.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 09:09
Source
TradingView
TradingView Direct company coverage

RXRX Forecast — Price Target — Prediction for 2027

This article provides a forecast for Recursion Pharmaceuticals, Inc. (RXRX) stock, including analyst price targets and ratings. It details the company's financial performance, such as recent earnings and revenue, and answers common questions about its stock performance, market ca

Tone
Positive 61/100
Event
Earnings
Published
26 Jun 2026 04:09
Source
TradingView
Stock Titan Direct company coverage

Recursion (NASDAQ: RXRX) director receives 88,424-share restricted stock grant

Recursion Pharmaceuticals (NASDAQ: RXRX) director Robert Hershberg was granted 88,424 restricted stock units (RSUs) as a routine award under the company’s Outside Director Compensation Policy. These RSUs vest on the earlier of June 17, 2027, or the day before the company’s 2027 a

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Recursion (NASDAQ: RXRX) director gets 88,424 RSUs, sells 3,963 shares

Recursion Pharmaceuticals, Inc. director Namandje Bumpus received a grant of 88,424 restricted stock units (RSUs) on June 17, 2026, which vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholders’ meeting. Concurrently, on June 18, 2026, Bumpus sold 3,9

Tone
Negative 41/100
Event
Market update
Published
23 Jun 2026 14:12
Source
Stock Titan